Health · 25 views
Continuing tirzepatide at full dose helps preserve weight loss over 112 weeks
New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated dose (MTD) of tirzepatide are seven times…
AI Summary
Research presented at the European Congress on Obesity suggests that continuing tirzepatide at its full dose can help individuals maintain weight loss over a prolonged period. The study found that those who remained on the maximum tolerated dose of tirzepatide were significantly more likely to preserve their weight loss compared to those who stopped treatment.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Ketamine reveals shifting brain activity patterns linked to depression improvement in older adultsContinue reading
- New research reveals underlying mechanisms of eye inflammationContinue reading
- We know how to prevent black lung, so why are workers still dying?Continue reading
- A cancer survivor hoped to work — then she lost her Medicaid disability coverageContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow